CytoBioscience, Inc.
About CytoBioscience, Inc.
Our Specialty is in vitro safety pharmacology
- Contracted by the FDA to provide ion channel screening services in support of the CiPA intiative
- Recognized experts and thought leaders
- Working with our clients do design studies
- Putting results in context
*…We don’t just provide data, we provide... Show more »
Our Specialty is in vitro safety pharmacology
- Contracted by the FDA to provide ion channel screening services in support of the CiPA intiative
- Recognized experts and thought leaders
- Working with our clients do design studies
- Putting results in context
…We don’t just provide data, we provide solutions
With decades of ion channel experience, CytoBioScience is uniquely positioned to be your one stop shop for in vitro safety pharmacology. From the CiPA ion channel panel to stem cells and in silico modeling, all aspects of the safety characterization of your compounds can be carried out. We also offer GLP capabilities and dose formulation analysis.
- With the use of our CytoPatch4 - the “hands-free” manual patch clamp platform, we also offer higher throughput ion channel screening services
- With our portfolio of capabilities, we can support screening of compounds from discovery through IND enabling studies
- We are proud to have been contracted by the FDA to provide ion channel screening services in support of the CiPA intiative
Our Services (15)
Patch Clamp Recording
Comprehensive in vitro Proarrhythmia Assay (CiPA)
The new strategy, entitled “Comprehensive
In Vitro Proarrhythmia Assay” (CiPA), shifts the emphasis
away from QT-prolongation and focuses on predicting
proarrhythmic torsadogenic hazard risk through an
expansion of the in vitro component of nonclinical safety
evaluation, which could be performed in the discovery
stage of... Show more »
The new strategy, entitled “Comprehensive
In Vitro Proarrhythmia Assay” (CiPA), shifts the emphasis
away from QT-prolongation and focuses on predicting
proarrhythmic torsadogenic hazard risk through an
expansion of the in vitro component of nonclinical safety
evaluation, which could be performed in the discovery
stage of drug development to guide selection of candidate
compounds with the most favorable profiles. This new approach is intended to provide a
more accurate representation of the torsadogenic potential
compared to the current focus on delayed repolarization.
It is anticipated that CiPA will reduce or eliminate the
necessity for conducting a thorough QT study during clinical
development.
hERG Channel Inhibition Assay
The human ether-a-go-go related gene (hERG) encodes the inward rectifying voltage gated potassium channel in the heart (IKr) which is involved in cardiac repolarisation.
Inhibition of the hERG current causes QT interval prolongation resulting in potentially fatal ventricular tachyarrhythmia called Torsade de Pointes. If hERG inhibition occurs we recommend CiPA assays as second phase.
The human ether-a-go-go related gene (hERG) encodes the inward rectifying voltage gated potassium channel in the heart (IKr) which is involved in cardiac repolarisation.
Inhibition of the hERG current causes QT interval prolongation resulting in potentially fatal ventricular tachyarrhythmia called Torsade de Pointes. If hERG inhibition occurs we recommend CiPA assays as second phase.
Ion Channel Screening Assays
Microelectrode Array (MEA) Recordings
Microelectrode array assay is used to determine cardiac action potential and/or ion channel activity using Human iPSC-Cardio Myocytes
Microelectrode array assay is used to determine cardiac action potential and/or ion channel activity using Human iPSC-Cardio Myocytes
In vitro Ion Channel Assays
In vitro Cardiotoxicity Screening
Drug Discovery & Development
Drug Discovery & Development Services
Drug Discovery & Development Services
In silico Cardiac Safety Assessment
Cell Electrophysiology
In vitro Toxicity Testing
Cell-Based Assays
Toxicology
Formulation Services
Electrophysiology
Electrophysiology Services
Electrophysiology Services
Not finding what you're looking for?
Get info on this provider's capabilities without requesting a quote.Christa Nutzhorn
Business Development
CytoBioscience, Inc. has not received any reviews.
CytoBioscience, Inc. has not received any endorsements.